

P A T E N T C L A I M S

1. Use of one or more steroids conjugated with one or more mammalian proteins for the manufacture of a pharmaceutical composition for the treatment or 5 diagnosis of solid cancers or hematological malignancies, wherein the steroid is not a cytostaticum.
2. Use according to claim 1, wherein the steroid is selected among: testosterone, estrogen, estradiol, progesterone, cortisol, glucocorticoids or any 10 known analogs thereof.
3. Use according to claim 1 or 2, wherein the mammalian proteins are selected among globular proteins, plasma proteins, albumins, binders or antibodies of selective human tumoral cell antigens.
- 15 4. Use according to claim 3, wherein the mammalian protein is human albumin or bovine serum albumin.
5. Use according to any of the claims 1-4, wherein the pharmaceutical composition further comprises a cytoskeleton acting drug. 20
6. Use according to claim 5, wherein the cytoskeleton acting drug is Taxol® or Taxotere®.
7. Use according to any of the claims 1-6, wherein the pharmaceutical composition further comprises one of an antiandrogen, an antiestrogen and an antiprogesterin in case that the tumor to be treated or 25 diagnosed is bearing testosterone-, estrogen- or progesterone- receptors, respectively
8. Use according to claim 7, wherein the 30 antiandrogen is cyproterone acetate or flutamide.
9. Use according to claim 7, wherein the antiestrogen is tamoxifene.
10. Use according to claim 7, wherein the anti-

progesterone is RU486.

11. Use according to any of the claims 1-10, wherein the solid cancer is selected among: prostate adenocarcinoma (hormone sensitive or resistant) and
5 its metastases, breast cancer and its metastases in any places, pheochromocytomas and their metastases, bone tumor and their metastases and brain tumor (neurobrastomas).

12. Use according to any of the claims 1-10,
10 wherein the haematological malignancies are selected among acute and chronic myeloid leukaemia, acute and chronic lymphoid leukaemia and lymphomas (B and T).

13. Pharmaceutical composition comprising one or more steroids, which are not cytostaticum, conjugated with mammalian proteins and a cytoskeleton-
15 acting drug.

14. Pharmaceutical composition according to claim 2, wherein the steroid is selected among: testosterone, estrogen, estradiol, progesterone, cortisol, glucocorticoids or any known analogs thereof.
20

15. Pharmaceutical composition according to claim 13 or 14, wherein the mammalian proteins are selected among globular proteins, plasma proteins, albumins, binders or antibodies of selective human
25 tumoral cell antigens.

16. Pharmaceutical composition according to claim 15, wherein the mammalian protein is human albumin or bovine serum albumin.

17. Pharmaceutical composition according to any
30 of the claims 13 to 16, wherein the cytoskeleton acting drug is Taxol® or Taxotere®.

18. Pharmaceutical composition according to any of the claims 13 to 17, which further comprises an

antiandrogen, an antiestrogen and an antiprogestin in case that the tumor to be treated or diagnosed is bearing testosterone-, estrogen- or progesterone-receptors, respectively.

5 19. Use of a pharmaceutical composition according to any of the claims 13-18, or a pharmaceutical composition prepared according to any of the claims 1-12, for the treatment of solid cancer or haematological malignancies.

10 20. Use according to claim 19, wherein the solid cancer is selected among: prostate adenocarcinoma (hormone sensitive or resistant) and its metastases, breast cancer and its metastases in any places, pheochromocytomas and their metastases, bone
15 tumor and their metastases and brain tumor (neurobrastomas).

 21. Use according to claim 19, wherein the haematological malignancies are selected among: acute and chronic myeloid leukaemia, acute and chronic lymphoid leukaemia and lymphomas (B and T).

20 22. Diagnostic method for the detection of solid cancer or haematological disorders, comprising the following steps:

 i) contacting the specimens with a solution
25 of a pharmaceutical composition according to claim 1;
 ii) detecting the amount of conjugate of steroid conjugated to mammalian protein is bound to the specimen.

30 23. Method according to claim 22, wherein the conjugate further comprise a labelling.

 24. Kit comprising:

 a pharmaceutical composition comprising one or

more steroids, which are not cytostaticum, conjugated with a mammalian protein; and
a pharmaceutical composition comprising a cytoskeleton acting drug, or

5 one of an antiandrogen, an antiestrogen and an antiprogesterin in case that the tumor is bearing testosterone-, estrogen- or progesterone- receptors, respectively.

25. Kit according to claim 24, comprising:

10 a pharmaceutical composition comprising one or more steroids, which are not cytostaticum, conjugated with a mammalian protein; and
a pharmaceutical composition comprising a cytoskeleton acting drug, and
15 one of an antiandrogen, an antiestrogen and an antiprogesterin in case that the tumor is bearing testosterone-, estrogen- or progesterone- receptors, respectively.